Amgen Inc. AMGN presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor, Repatha ...
Repatha (140 mg) or placebo will be self-administered subcutaneously every two weeks for a minimum of four years. Follow-up of all randomized patients is planned to continue for a minimum of four ...
Amgen Inc. AMGN announced that the FDA has approved a new, monthly single-dose administration option for its PCSK9 inhibitor, Repatha. The Repatha Pushtronex system, an on-body infusor with a ...
Amgen has a new tool to employ in its battle with Sanofi and Regeneron for PCSK9 market dominance. The drugmaker said today that the FDA has approved a new hands-free injector for a once-monthly dose ...
Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...
Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha ® (evolocumab) Injection, the first proprotein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results